# A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

> **NCT02981446** · PHASE3 · COMPLETED · sponsor: **Santen Pharmaceutical Co., Ltd.** · enrollment: 370 (actual)

## Conditions studied

- Open Angle Glaucoma or Ocular Hypertension

## Interventions

- **DRUG:** DE-117
- **DRUG:** Latanoprost ophthalmic solution

## Key facts

- **NCT ID:** NCT02981446
- **Lead sponsor:** Santen Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02981446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02981446, "A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT02981446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*